JP2013506437A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013506437A5 JP2013506437A5 JP2012533282A JP2012533282A JP2013506437A5 JP 2013506437 A5 JP2013506437 A5 JP 2013506437A5 JP 2012533282 A JP2012533282 A JP 2012533282A JP 2012533282 A JP2012533282 A JP 2012533282A JP 2013506437 A5 JP2013506437 A5 JP 2013506437A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- item
- nucleic acid
- agent
- toll
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 150000007523 nucleic acids Chemical class 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 108010040721 Flagellin Proteins 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 102000002689 Toll-like receptor Human genes 0.000 claims description 7
- 108020000411 Toll-like receptor Proteins 0.000 claims description 7
- 108010051696 Growth Hormone Proteins 0.000 claims description 6
- 102100038803 Somatotropin Human genes 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003970 toll like receptor agonist Substances 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000000122 growth hormone Substances 0.000 claims description 4
- 229960001438 immunostimulant agent Drugs 0.000 claims description 4
- 239000003022 immunostimulating agent Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102100024819 Prolactin Human genes 0.000 claims description 2
- 108010057464 Prolactin Proteins 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 229940097325 prolactin Drugs 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 244000045947 parasite Species 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24925309P | 2009-10-06 | 2009-10-06 | |
| US61/249,253 | 2009-10-06 | ||
| US24959609P | 2009-10-07 | 2009-10-07 | |
| US61/249,596 | 2009-10-07 | ||
| PCT/US2010/051646 WO2011044246A1 (en) | 2009-10-06 | 2010-10-06 | Use of toll-like receptor and agonist for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015128384A Division JP2015165821A (ja) | 2009-10-06 | 2015-06-26 | がんを処置するためのトール様受容体およびトール様受容体アゴニストの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013506437A JP2013506437A (ja) | 2013-02-28 |
| JP2013506437A5 true JP2013506437A5 (OSRAM) | 2013-11-14 |
| JP5796014B2 JP5796014B2 (ja) | 2015-10-21 |
Family
ID=43857117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012533282A Expired - Fee Related JP5796014B2 (ja) | 2009-10-06 | 2010-10-06 | がんを処置するためのトール様受容体およびトール様受容体アゴニストの使用 |
| JP2015128384A Pending JP2015165821A (ja) | 2009-10-06 | 2015-06-26 | がんを処置するためのトール様受容体およびトール様受容体アゴニストの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015128384A Pending JP2015165821A (ja) | 2009-10-06 | 2015-06-26 | がんを処置するためのトール様受容体およびトール様受容体アゴニストの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9205095B2 (OSRAM) |
| EP (1) | EP2486134B1 (OSRAM) |
| JP (2) | JP5796014B2 (OSRAM) |
| KR (1) | KR20120104177A (OSRAM) |
| CN (1) | CN104136614B (OSRAM) |
| AP (1) | AP2012006253A0 (OSRAM) |
| AU (1) | AU2010303464B2 (OSRAM) |
| BR (1) | BR112012011331B8 (OSRAM) |
| CA (1) | CA2777198C (OSRAM) |
| EA (1) | EA021842B1 (OSRAM) |
| ES (1) | ES2457518T3 (OSRAM) |
| IL (1) | IL219060A (OSRAM) |
| MX (1) | MX2012004095A (OSRAM) |
| MY (1) | MY163110A (OSRAM) |
| WO (1) | WO2011044246A1 (OSRAM) |
| ZA (1) | ZA201202500B (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1838340B1 (en) | 2004-12-22 | 2018-04-04 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
| CN102170911B (zh) | 2008-08-01 | 2014-07-02 | 克里夫兰生物实验室公司 | 用于治疗再灌注损伤的方法 |
| KR20140030132A (ko) | 2011-01-10 | 2014-03-11 | 클리브랜드 바이오랩스, 아이엔씨. | 암을 치료하기 위한 톨-유사 수용체 효능제의 용도 |
| WO2014098649A1 (en) * | 2012-12-18 | 2014-06-26 | Obschestvo S Ogranichennoy Otvetstvennostyu "Panacela Labs" | Compositions and methods using toll-like receptor 5 and toll-like receptor agonist |
| WO2015080631A1 (en) * | 2013-11-27 | 2015-06-04 | Obschestvo S Ogranichennoy Otvetstvennost`Yu "Panacela Labs" | Improved expression vector for toll-like receptor and agonist and use for treating cancer |
| US10202426B2 (en) | 2014-07-30 | 2019-02-12 | Genome Protection, Inc. | Flagellin compositions and uses |
| US10537626B2 (en) | 2014-10-07 | 2020-01-21 | Cytlimic Inc. | HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell |
| US10183056B2 (en) | 2014-10-16 | 2019-01-22 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
| JP6898225B2 (ja) | 2015-03-09 | 2021-07-07 | サイトリミック株式会社 | Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
| EP3797794A1 (en) | 2015-04-07 | 2021-03-31 | Cytlimic Inc. | Medicine comprising a toll like receptor 3 agonist and a lag-3 protein |
| KR101634380B1 (ko) | 2015-06-23 | 2016-06-28 | 한국생산기술연구원 | Tlr5 아고니스트 단백질의 생산방법 |
| CN105801709B (zh) * | 2016-04-29 | 2019-10-08 | 北京纽莱福生物科技有限公司 | CBLB502-Fc融合蛋白及其制备方法 |
| AU2017342189B2 (en) | 2016-10-11 | 2023-09-21 | Nec Corporation | Medicine |
| WO2018088933A1 (en) * | 2016-11-14 | 2018-05-17 | Limited Liability Company "Panacela Labs" | Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist |
| US11029609B2 (en) * | 2016-12-28 | 2021-06-08 | Asml Netherlands B.V. | Simulation-assisted alignment between metrology image and design |
| WO2018210279A1 (zh) * | 2017-05-16 | 2018-11-22 | 科济生物医药（上海）有限公司 | Toll样受体激动剂与免疫效应细胞的联用 |
| UY37816A (es) | 2017-07-20 | 2019-02-28 | Spogen Biotech Inc | Polipéptidos bioactivos para mejorar la protección, crecimiento y productividad en plantas |
| EP3768285A1 (en) | 2018-03-19 | 2021-01-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US12440536B2 (en) | 2018-05-18 | 2025-10-14 | The University Of Hong Kong | Compositions of toll-like receptor 5 (TLR5) agonist and methods of use thereof |
| WO2020041720A1 (en) | 2018-08-24 | 2020-02-27 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| EP3921432A1 (en) | 2019-02-04 | 2021-12-15 | Codiak BioSciences, Inc. | Membrane protein scaffolds for exosome engineering |
| US12233356B2 (en) | 2019-03-21 | 2025-02-25 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| CA3133314A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Extracellular vesicle conjugates and uses thereof |
| US12502427B2 (en) | 2019-03-21 | 2025-12-23 | Lonza Sales Ag | Extracellular vesicles for vaccine delivery |
| US20220251200A1 (en) | 2019-07-03 | 2022-08-11 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
| JP2022549328A (ja) | 2019-09-25 | 2022-11-24 | コディアック バイオサイエンシーズ， インコーポレイテッド | 細胞外小胞組成物 |
| US20230114434A1 (en) | 2020-03-13 | 2023-04-13 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
| JP2023518414A (ja) | 2020-03-20 | 2023-05-01 | コディアック バイオサイエンシーズ， インコーポレイテッド | 治療のための細胞外小胞 |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| JP7598660B2 (ja) * | 2020-06-04 | 2024-12-12 | ザ カトリック ユニバーシティ オブ コリア インダストリー－アカデミック コーオペレイション ファウンデーション | フラジェリン由来のｔｌｒ５アゴニストを有効成分として含む抗がん剤組成物 |
| WO2021248133A1 (en) | 2020-06-05 | 2021-12-09 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
| US20240241020A1 (en) | 2020-09-23 | 2024-07-18 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| US20240082389A1 (en) | 2020-09-23 | 2024-03-14 | Lonza Sales Ag | Methods of producing extracellular vesicles |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| WO2025196053A1 (en) * | 2024-03-18 | 2025-09-25 | Istituto Europeo Di Oncologia S.R.L. | Flagellin-related peptides and uses thereof |
| EP4620482A1 (en) * | 2024-03-18 | 2025-09-24 | Istituto Europeo di Oncologia S.r.l. | Flagellin-related peptides and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703146B2 (en) * | 2001-04-20 | 2014-04-22 | Institute For Systems Biology | Toll-like receptor 5 ligands and methods of use |
| EP1838340B1 (en) * | 2004-12-22 | 2018-04-04 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
| CA2594612A1 (en) * | 2005-01-19 | 2006-07-27 | Vaxinnate Corporation | Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response |
| WO2009102818A1 (en) * | 2008-02-11 | 2009-08-20 | Cleveland Biolabs, Inc. | Method for reducing the effects of chemotheraphy using flagellin related polypeptides |
-
2010
- 2010-10-06 CA CA2777198A patent/CA2777198C/en active Active
- 2010-10-06 WO PCT/US2010/051646 patent/WO2011044246A1/en not_active Ceased
- 2010-10-06 JP JP2012533282A patent/JP5796014B2/ja not_active Expired - Fee Related
- 2010-10-06 EA EA201290140A patent/EA021842B1/ru unknown
- 2010-10-06 KR KR1020127008759A patent/KR20120104177A/ko not_active Ceased
- 2010-10-06 AP AP2012006253A patent/AP2012006253A0/xx unknown
- 2010-10-06 AU AU2010303464A patent/AU2010303464B2/en not_active Ceased
- 2010-10-06 MX MX2012004095A patent/MX2012004095A/es active IP Right Grant
- 2010-10-06 ES ES10822611.9T patent/ES2457518T3/es active Active
- 2010-10-06 CN CN201080055226.1A patent/CN104136614B/zh not_active Expired - Fee Related
- 2010-10-06 US US13/500,552 patent/US9205095B2/en active Active
- 2010-10-06 MY MYPI2012001519A patent/MY163110A/en unknown
- 2010-10-06 EP EP10822611.9A patent/EP2486134B1/en active Active
- 2010-10-06 BR BR112012011331A patent/BR112012011331B8/pt not_active IP Right Cessation
-
2012
- 2012-04-04 IL IL219060A patent/IL219060A/en active IP Right Grant
- 2012-04-05 ZA ZA2012/02500A patent/ZA201202500B/en unknown
-
2015
- 2015-06-26 JP JP2015128384A patent/JP2015165821A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | STING agonist-derived LNP-mRNA vaccine enhances protective immunity against SARS-CoV-2 | |
| Akkın et al. | A review on cancer immunotherapy and applications of nanotechnology to chemoimmunotherapy of different cancers | |
| Luo et al. | Activation of stimulation of interferon genes (STING) signal and cancer immunotherapy | |
| Jin et al. | Nanoparticle‐mediated delivery of inhaled immunotherapeutics for treating lung metastasis | |
| Yan et al. | pH-responsive nanoparticles for cancer immunotherapy: a brief review | |
| Martins et al. | Vaccine adjuvant uses of poly-IC and derivatives | |
| Vasilakos et al. | The use of Toll-like receptor 7/8 agonists as vaccine adjuvants | |
| Gutjahr et al. | Biodegradable polymeric nanoparticles-based vaccine adjuvants for lymph nodes targeting | |
| Wong et al. | The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation | |
| Moser et al. | Influenza virosomes as vaccine adjuvant and carrier system | |
| Gosu et al. | Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signaling | |
| Nagatomo et al. | Cholesteryl pullulan encapsulated TNF‐α nanoparticles are an effective mucosal vaccine adjuvant against influenza virus | |
| WO2023031392A3 (en) | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine | |
| CY1118373T1 (el) | Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος | |
| JP6603216B2 (ja) | 殺腫瘍性および抗菌性の組成物ならびに方法 | |
| Han et al. | Toll-like receptor 3-induced immune response by poly (d, l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy | |
| Andón et al. | Innate and adaptive responses of intratumoral immunotherapy with endosomal toll-like receptor agonists | |
| US20110218169A1 (en) | Pirfenidone/Toll-Like Receptor (TLR) Agonist Compounds and Methods of Treating Neutropenia | |
| Chen et al. | Maximizing TLR9 activation in cancer immunotherapy with dual-adjuvanted spherical nucleic acids | |
| Wakita et al. | An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen | |
| Shen et al. | Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide | |
| Shen et al. | Progress update on STING agonists as vaccine adjuvants | |
| JP2006502228A5 (OSRAM) | ||
| Li et al. | Toll-like receptors 7/8: a paradigm for the manipulation of immunologic reactions for immunotherapy | |
| Wu et al. | Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy |